close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Warrant (NQ:TVGNW)

0.0449 +0.0003 (+0.67%)
Streaming Delayed Price Updated: 3:20 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tevogen Bio Holdings Inc. - Warrant

< Previous 1 2 3 4 5 6 Next >
News headline image
Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Set to Join Russell 3000® Index
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Reports First Quarter 2024 Financial Results
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
From Tevogen Bio Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today